RegisterLogin

Copanlisib

CAT: 0804-HY-15346-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15346-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity[1].
CAS Number
[1032568-63-0]
Product Name Alternative
BAY 80-6946
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; PI3K
Type
Reference compound
Related Pathways
Apoptosis; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BAY-80-6946.html
Purity
99.35
Smiles
O=C(C1=CN=C(N)N=C1)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C5=NCCN25
Molecular Formula
C23H28N8O4
Molecular Weight
480.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Liu N, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013 Nov;12 (11) :2319-30.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
Citation 01
Bioorg Chem. 2025 Apr 5:160:108424.|Blood Adv. 2022 Apr 12;6 (7) :2346-2360.|Blood. 2019 Jan 3;133 (1) :70-80.|Br J Cancer. 2025 Oct 6.|Breast Cancer Res Treat. 2020 Jan;179 (2) :337-347.|Cancer Discov. 2025 Jan 13;15 (1) :202-226.|Cancer Lett. 2022 Jan 1:524:151-160.|Carbohydr Polym. 2024 Feb 15:326:121637.|Cell Biosci. 2020 Feb 12;10:16.|Cell Biosci. 2022 Aug 2;12 (1) :122.|Cell Biosci. 2022 Dec 30;12 (1) :210.|Front Immunol. 2021 Oct 15;12:699478.|Front Oncol. 2021 Jul 13:11:704042.|Genes Dis. 2021 Jul 1;9 (6) :1650-1661.|J Clin Invest. 2021 Dec 15;131 (24) :e140436.|J Immunother Cancer. 2022 Mar;10 (3) :e003402.|J Oncol. 2022 Apr 29;2022:1515416.|Mol Cancer Ther. 2025 Jul 10.|Mol Cancer. 2023 Mar 30;22 (1) :64.|Mol Cancer. 2024 Sep 30;23 (1) :215.|Mol Carcinog. 2024 Apr 17|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Nat Cancer. 2024 Aug;5 (8) :1250-1266.|RSC Adv. 2019 Feb 21;9 (11) :6409-6418.|Sci Rep. 2025 Aug 10;15 (1) :29265.|Science. 2017 Dec 1;358 (6367) :eaan4368.|Signal Transduct Target Ther. 2025 Oct 31;10 (1) :356.|Theranostics. 2020 Jan 1;10 (4) :1531-1543.|Université de Lausanne. 2024 Feb 7.|bioRxiv. 2025 Jan 16:2025.01.10.632413.|Br J Cancer. 2025 Oct 6.|Front Oncol. 2022 Sep 8:12:944537.

Related Products

CatalogName

Alternative Products

CatalogName
S2802-5mgCopanlisib
206945Copanlisib HCl
BUP06251-01Copanlisib dihydrochloride
TRC-B119062-100MGCopanlisib-D8
TRC-B119065-100MGCopanlisib impurity A
TRC-C757207-100MGCopanlisib-13C
204570Copanlisib free base
MBS384334-01BAY 80-6946 (Copanlisib)
T70758-01Copanlisib HCl hydrate
TRC-B119055-100MGCopanlisib impurity B

Popular Products